Hubei Goto Biopharm Co.,Ltd. (SHE:300966)

Hubei Goto Biopharm Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	94.66	141.18	181.97	438.42	209.91	28.96
Trading Asset Securities	0	0	0	15.01	0.1	-
Cash & Short-Term Investments	94.66	141.18	181.97	453.43	210.02	28.96
Cash Growth	-27.46%	-22.42%	-59.87%	115.90%	625.10%	-77.66%
Accounts Receivable	196.9	214.26	235.4	269.36	243.86	312.53
Other Receivables	2.59	2.05	2.15	1.88	2.09	0.72
Receivables	199.49	216.31	237.54	271.25	245.95	313.26
Inventory	460.12	384.8	396.16	432.5	371.24	200.74
Prepaid Expenses	-	-	-	-	1.68	1.27
Other Current Assets	25.42	27.7	54.06	56.56	29.37	35.42
Total Current Assets	779.69	770	869.73	1,214	858.26	579.64
Property, Plant & Equipment	1,891	1,849	1,391	610.94	256.57	198.11
Long-Term Investments	48.3	48.27	48.24	48.08	14.47	-
Other Intangible Assets	49.05	49.88	51	43.14	27.82	21.06
Long-Term Deferred Tax Assets	55.18	37.29	22.62	17.89	8.82	3.43
Long-Term Deferred Charges	7.14	9.69	13.3	13.96	0.97	1.93
Other Long-Term Assets	26.74	25.78	51.96	121.56	44.34	0.26
Total Assets	2,857	2,790	2,448	2,069	1,211	804.43
Accounts Payable	459.8	459.91	532.24	205.52	138.17	74.12
Accrued Expenses	6.38	12.43	9.25	9.58	7.51	6.4
Short-Term Debt	213.25	294.3	110.09	321.63	143.41	118
Current Portion of Long-Term Debt	63.02	24.55	22.27	5.24	-	-
Current Portion of Leases	-	0.06	0.45	1.98	11.47	21.77
Current Income Taxes Payable	0.89	0.08	2.8	7.21	11.27	5.73
Current Unearned Revenue	0.22	1.23	3.47	2.01	3.7	0.19
Other Current Liabilities	19.28	15.13	5.84	22.79	17.65	20.92
Total Current Liabilities	762.84	807.69	686.41	575.97	333.18	247.13
Long-Term Debt	992.51	812.64	652.37	437.04	-	-
Long-Term Leases	-	-	0.54	4.41	6.67	9.75
Long-Term Unearned Revenue	142.76	150.25	84.33	69.71	42.98	7.69
Long-Term Deferred Tax Liabilities	0.74	0.01	0.29	0.97	0	-
Other Long-Term Liabilities	-	4.65	0.03	0.05	-	0.02
Total Liabilities	1,899	1,775	1,424	1,088	382.83	264.58
Common Stock	115.28	115.28	115.28	115.28	115.28	86.28
Additional Paid-In Capital	411.07	410.6	410.77	409.11	409.11	243.92
Retained Earnings	268.33	300.77	330.2	307.2	282.67	204.34
Comprehensive Income & Other	96.48	96.49	96.49	96.51	-	-
Total Common Equity	871.4	923.14	952.75	928.09	807.05	534.54
Minority Interest	86.51	91.5	71.03	53.07	21.36	5.31
Shareholders' Equity	957.91	1,015	1,024	981.16	828.42	539.85
Total Liabilities & Equity	2,857	2,790	2,448	2,069	1,211	804.43
Total Debt	1,269	1,132	785.73	770.3	161.54	149.51
Net Cash (Debt)	-1,174	-990.37	-603.75	-316.87	48.47	-120.55
Net Cash Per Share	-10.36	-8.61	-5.25	-2.76	0.46	-1.40
Filing Date Shares Outstanding	124.47	115.28	115.28	115.28	115.28	115.28
Total Common Shares Outstanding	124.47	115.28	115.28	115.28	115.28	86.28
Working Capital	16.85	-37.69	183.33	637.76	525.08	332.52
Book Value Per Share	7.00	8.01	8.26	8.05	7.00	6.20
Tangible Book Value	822.35	873.26	901.75	884.95	779.23	513.48
Tangible Book Value Per Share	6.61	7.58	7.82	7.68	6.76	5.95
Buildings	-	506.33	129.73	108.67	95.53	91.93
Machinery	-	820.79	207.89	196.16	180.78	175.11
Construction In Progress	-	694.41	1,182	411.99	66.38	5.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.